JPH0360272B2 - - Google Patents

Info

Publication number
JPH0360272B2
JPH0360272B2 JP61015862A JP1586286A JPH0360272B2 JP H0360272 B2 JPH0360272 B2 JP H0360272B2 JP 61015862 A JP61015862 A JP 61015862A JP 1586286 A JP1586286 A JP 1586286A JP H0360272 B2 JPH0360272 B2 JP H0360272B2
Authority
JP
Japan
Prior art keywords
hap
glucomannan
artificial
materials
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP61015862A
Other languages
Japanese (ja)
Other versions
JPS62176454A (en
Inventor
Katsukyo Sakurai
Tooru Nakajima
Masahiro Sato
Giichi Yoshida
Minoru Morimatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentax Corp
Seikagaku Corp
Original Assignee
Seikagaku Corp
Asahi Kogaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp, Asahi Kogaku Kogyo Co Ltd filed Critical Seikagaku Corp
Priority to JP61015862A priority Critical patent/JPS62176454A/en
Publication of JPS62176454A publication Critical patent/JPS62176454A/en
Publication of JPH0360272B2 publication Critical patent/JPH0360272B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Materials For Medical Uses (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

[産業上の利用分野] 本発明は、形成外科材料として有用な骨類似成
形物に関するものである。 [従来技術及びその問題点] 近年、医療福祉の向上のため、生体と直接ある
いは間接に接触するような条件のもとで機能する
材料「生医学材料又はバイオマテリアル」の開発
が期待されている。生体は生体を構成する種々の
器官が、相互に関連を保ちながら独自の機能を果
たし継続維持されて始めて生命が存在することと
なるが、これら生体を構成する構造材料の機能欠
損を補う目的で、生体高分子をモデルとした生医
学材料の開発が行われて来た。 生医学材料には、使用目的から、永久埋植を目
標としたり、材料の表面に偽内膜の形成を促して
本来の機能を行わせたり、本来の器官が自力で再
生するまでの間、機能を代行させ、再生後は崩壊
消滅することによるもの等、目的応用により種々
の性質が望まれる。 また、性医学材料には、一般的に直接あるいは
間接に、生体ないし生体由来物質との接触が行わ
れることから、生体親和性、生体内劣化性、抗血
栓性、安全性に対する配慮が求められる。人工材
料を生体と接触させると、生体は、人工材料から
影響を受けると同時に、人工材料も生体から影響
を受ける。生体は一般に異物との接触を嫌い、異
物の侵入を拒絶し、昂じては、異物反応のために
生体組織細胞の壊死を招く。また、人工材料の側
では材料の生体内劣化、分解が問題となり、その
劣化分解過程の生成物に対する安全性の検討が重
要である。 現在、生医学材料として用いられているものは
多種挙げられるが、本発明に係る生医学材料は、
形成を目的とし、人工鼻、人工耳殻、人工乳房等
の補綴材料、経皮的アクセスデバイスや骨、関節
の硬組織に付随した軟骨の置換のために生体内埋
植を目的とする骨類似成形物である。 これまで、形成を目的とした医用高分子材料と
しては、シリココーンやテフロンのように、生体
に対して不活性と考えられて来た材料や、各種ヒ
ドロゲルのように材料表面に高エネルギーを与え
たり、表面修飾により生体親和性の優れたハイブ
リツド複合材料の開発の試みがなされて来た。し
かし、いずれも生体適合性及び安全性の面から充
分その目的を達成されたものは得られていない。 本発明者らは、人工骨、人工歯根、骨セメント
等の人工硬組織に実用化されているハイドロキシ
アパタイト(以下「HAP」という)焼結体の有
する生体親和性や、生体内抗劣化性に着目し、鋭
意検討を行つた結果、生体親和性、抗劣化性に加
えて、成形が容易で、弾力性及び安全性の高い新
規な骨類以成形物の創生に到達した。 [発明の構成] 本発明の骨類似成形物は、HAP、グリコサミ
ノグリカン(以下「GAG」という)、グルコマン
ナン及びエピハロヒドリンを反応せしめてなるこ
とを特徴とするものである。 本発明に用いるHAPは、次式: Ca10(PO46(OH)2で示される硬骨や歯骨の主
成分であり、例えば、湿式法では次式: Ca(NO32+(NH42HPO4 pH8〜10 ――――――→ Ca10(PO46(OH)2 により、乾式法では次式: Ca2P2O7+CaCO3 1200℃ ――――→ 水蒸気Ca10(PO46(OH)2 等の公知方法により合成され、人工歯根や人工骨
として用いる為には更に成形後のケーキ状アパタ
イトを1000〜1250℃で焼結して機械的強度を増し
て使用されているものである。 本発明に用いるGAGとしては、コンドロイチ
ン硫酸類、ヒアルロン酸、ヘパリン、ヘパラン硫
酸等が挙げられ、特にコンドロイチン硫酸Aやコ
ンドロイチン硫酸Cが好ましく、通常、医薬品と
して市販されている品質のものが用いられる。 本発明に用いるグルコマンナンとしては、通
常、市販のグルコマンナン粉を用いるが、不純物
が多い場合には精製が必要である。 本発明に用いるエピハロヒドリンとしては、エ
ピクロルヒドリン及びエピブロムヒドリン等が挙
げられる。 HAP、GAG及びグルコマンナンの使用量は、
HAP 100重量部、GAG 100〜5重量%、グルコ
マンナン 200〜5重量部であることが好ましい。 エピハロヒドリンの使用量は、GAGを構成し
ている繰り返し糖の10倍のモル数であることが好
ましい。 本発明の骨類似成形物は、例えば、次のように
して製造することができる。 即ち、アルカリ性、好ましくはPH10〜12の水溶
液に、HAP、GAG、グルコマンナン及びエピハ
ロヒドリンを加えて練合し、均質なケーキとし、
用途に応じた型作りをする。このときのアルカリ
性水溶液の使用量は、HAP、GAG及びグルコマ
ンナンの合計量100重量部に対し、10〜5重量部
であることが好ましい。 成形済練合ケーキは、通常室温乃至150℃好ま
しくは室温乃至100℃で通常1時間乃至48時間反
応せしめ各構成成分相互の水酸基を介したマトリ
ツクス状架橋化を行うことにより弾力性に富む軟
骨様成形物を得ることができる。 [発明の効果] 本発明によれば、成形が容易で、弾力性及び酵
素分解抵抗性の高い骨類似成形物を提供すること
ができる。 [発明の実施例] 以下、実施例及び試験例により本発明を更に詳
細に説明するが、これらは、本発明の範囲を何ら
制限するものではない。 実施例 1 コンドロイチン硫酸ナトリウム5g及びグルコ
マンナン5gを0.01N NaOH水溶液100mlに溶解
し、練合しながらHAP 5g及びエピクロルヒド
リン9.25gを加え、粘土状ケーキを作つた。該ケ
ーキを木型により目的の形に成形し40℃の温浴中
で2時間反応し、次いで型枠をはずし騰水約5
中で5分間煮沸し、得られた反応形成物を0.1N
NaOH水溶液に一夜浸漬後、無菌水で洗浄した
後、無菌的に温風乾燥して軟骨様物質18.7gを得
た。該軟骨様物質の分析値を表に示す。 Ca 9.1% P 5.7% 水 分 25.0% グルクロン酸含量 7.8% 実施例 2〜9 HAP、コンドロイチン硫酸ナトリウム及びグ
ルコマンナン構成成分の量比を換えて反応を実施
例1に準じて実施し、1cm×1cm×1mmの軟骨様
物質片を調製した。
[Industrial Field of Application] The present invention relates to a bone-like molded product useful as a plastic surgery material. [Prior art and its problems] In recent years, in order to improve medical welfare, there are expectations for the development of "biomedical materials or biomaterials" that function under conditions of direct or indirect contact with living organisms. . A living body can only exist when the various organs that make up the living body perform their unique functions while maintaining relationships with each other, and are continuously maintained. , biomedical materials using biopolymers as models have been developed. Depending on the purpose of use, biomedical materials may be used for permanent implantation, for promoting the formation of a pseudoendometrium on the surface of the material to perform its original function, or for the period until the original organ regenerates on its own. Various properties are desired depending on the intended application, such as one that performs a function and collapses and disappears after regeneration. In addition, since sexual medical materials generally come into direct or indirect contact with living organisms or substances of biological origin, consideration must be given to biocompatibility, biodegradability, antithrombotic properties, and safety. . When an artificial material comes into contact with a living body, the living body is influenced by the artificial material, and at the same time, the artificial material is also influenced by the living body. Living organisms generally dislike contact with foreign substances and reject the invasion of foreign substances, leading to necrosis of living tissue cells due to foreign body reactions. Furthermore, on the side of artificial materials, in-vivo deterioration and decomposition of the materials are a problem, and it is important to consider the safety of the products of the deterioration and decomposition process. There are many types of biomedical materials currently used, but the biomedical materials according to the present invention include:
Bone analogues for the purpose of implantation in vivo for the purpose of implantation, prosthetic materials such as artificial noses, artificial ear shells, and artificial breasts, percutaneous access devices, and replacement of cartilage attached to bones and hard tissues of joints. It is a molded product. Until now, medical polymer materials for the purpose of formation have included materials that were thought to be inert to living organisms, such as silicone corn and Teflon, and materials that were thought to be inert to living bodies, such as various hydrogels, and materials that applied high energy to the material surface, such as various hydrogels. Attempts have been made to develop hybrid composite materials with excellent biocompatibility through surface modification. However, none of them has been able to sufficiently achieve their objectives in terms of biocompatibility and safety. The present inventors have investigated the biocompatibility and in vivo anti-deterioration properties of hydroxyapatite (hereinafter referred to as "HAP") sintered bodies, which are used in artificial hard tissues such as artificial bones, artificial tooth roots, and bone cement. As a result of careful research and biocompatibility, we have arrived at the creation of a new bone-like molded product that is easy to mold, has high elasticity, and is safe. [Structure of the Invention] The bone-like molded product of the present invention is characterized by being formed by reacting HAP, glycosaminoglycan (hereinafter referred to as "GAG"), glucomannan, and epihalohydrin. HAP used in the present invention is a main component of hard bones and dentary bones represented by the following formula: Ca 10 (PO 4 ) 6 (OH) 2 .For example, in the wet method, HAP is represented by the following formula: Ca (NO 3 ) 2 + ( NH 4 ) 2 HPO 4 pH8~10 ――――――→ Ca 10 (PO 4 ) 6 (OH) 2 According to the dry method, the following formula: Ca 2 P 2 O 7 +CaCO 3 1200℃ ――――→ It is synthesized by known methods such as water vapor Ca 10 (PO 4 ) 6 (OH) 2 , and in order to use it as an artificial tooth root or artificial bone, the cake-shaped apatite after molding is further sintered at 1000 to 1250°C to improve its mechanical strength. It is used with increasing number of people. GAGs used in the present invention include chondroitin sulfates, hyaluronic acid, heparin, heparan sulfate, etc., and chondroitin sulfate A and chondroitin sulfate C are particularly preferred, and those of quality commercially available as pharmaceuticals are usually used. Commercially available glucomannan powder is usually used as the glucomannan used in the present invention, but if it contains many impurities, purification is required. Epihalohydrin used in the present invention includes epichlorohydrin, epibromohydrin, and the like. The amount of HAP, GAG and glucomannan used is
Preferably, the amounts are 100 parts by weight of HAP, 100-5% by weight of GAG, and 200-5 parts by weight of glucomannan. The amount of epihalohydrin used is preferably 10 times the number of moles of the repeating sugar constituting GAG. The bone-like molded article of the present invention can be produced, for example, as follows. That is, HAP, GAG, glucomannan, and epihalohydrin are added to an alkaline aqueous solution, preferably PH 10 to 12, and kneaded to form a homogeneous cake.
Make a mold according to the purpose. The amount of alkaline aqueous solution used at this time is preferably 10 to 5 parts by weight based on 100 parts by weight of the total amount of HAP, GAG, and glucomannan. The shaped kneaded cake is usually reacted at room temperature to 150°C, preferably room temperature to 100°C, for usually 1 hour to 48 hours, and crosslinked in a matrix form through the hydroxyl groups between the constituent components, resulting in a highly elastic cartilage-like product. A molded product can be obtained. [Effects of the Invention] According to the present invention, it is possible to provide a bone-like molded product that is easy to mold and has high elasticity and resistance to enzymatic degradation. [Examples of the Invention] Hereinafter, the present invention will be explained in more detail with reference to Examples and Test Examples, but these are not intended to limit the scope of the present invention in any way. Example 1 5 g of sodium chondroitin sulfate and 5 g of glucomannan were dissolved in 100 ml of 0.01N NaOH aqueous solution, and while kneading, 5 g of HAP and 9.25 g of epichlorohydrin were added to make a clay cake. The cake was molded into the desired shape using a wooden mold, reacted for 2 hours in a 40°C hot bath, then the mold was removed and the cake was boiled in boiling water for about 5 hours.
The reaction product was boiled for 5 minutes in 0.1N
After being immersed in a NaOH aqueous solution overnight, it was washed with sterile water and dried with warm air aseptically to obtain 18.7 g of cartilage-like material. The analytical values of the cartilage-like substance are shown in the table. Ca 9.1% P 5.7% Water 25.0% Glucuronic acid content 7.8% Examples 2 to 9 The reaction was carried out according to Example 1 by changing the quantitative ratio of HAP, sodium chondroitin sulfate, and glucomannan components, and the reaction was carried out in a 1 cm × 1 cm A x1 mm piece of cartilage-like material was prepared.

【表】 なお、GAG及びエピクロルヒドリンの影響を
以下の試験例で検討する為にHAPとグルコマン
ナンの組成反応物を実施例に準じて調製して比較
例1とした。 実施例 10 HAP 5g、コンドロイチン硫酸ナトリウム5
g、ヒアルロン酸ナトリウム(分子量約100万)
0.5g、グルコマンナン5g及びエピクロルヒド
リン9.25gを0.01N NaOH水溶液 100ml中にて
練合し実施例1に準じて反応し軟骨様物質16.3g
を得た。 分析値 Ca 9.1% P 5.5% グルクロン酸換算ウロン酸値 7.2% 水 分 28.7% 試験例 1 酵素分解抵抗性 生体埋植時の劣化反応のモデルとして、ムコ
多糖分解酵素であるヒアルロニダーゼに対する
耐性を検討した。 実施例1により得た軟骨様物質1gを約1mm3
の角片に細断し、0.1M酢酸緩衝液(PH5.0)50
mlに浸漬し、牛睾丸ヒアルロニダーゼ(生化学
工業(株)・試薬グレード)0.1gを加え50℃で24
時間撹拌消化した。 該軟骨様物質片を別し、液をカルバゾー
ル硫酸法により測定したが、液中にウロン酸
は全く認められなかつた。このことから本検体
はヒアルロニダーゼにより分解されにくく生体
内劣化されにくいことが判明した。 2 血液適合性試験 生体親和性の一指標として、全血凝固時間測
定(臨床検査の意義と解釈(第2版)86ペー
ジ、吉利和監修、医学書院出版)により血液凝
固反応、血小板凝集反応、赤血球凝集反応に対
する本検体の作用を定性的に評価した。 直径0.7cm、長さ4cmのポリエチレン製チユ
ーブの底部をクランプして実施例1にて調製し
た軟骨様物質1mm3の角片30個を充填し、新鮮に
採血したヒト静脈血1〜2mlを加えた。対照の
凝固時間はチユーブと同じ大きさのガラス管に
本検体と血液を加えて測定した。各チユーブと
ガラス管を37℃にして30秒毎に傾けて血液の流
動性を調べた。凝固時間の終点は血液全体がゲ
ルに変つた時点とした。本検体を入れないで血
液だけを同様に処理したものを対照−1とし
た。結果を表に示す。
[Table] In order to examine the influence of GAG and epichlorohydrin in the following test example, a composition reaction product of HAP and glucomannan was prepared according to the example and used as Comparative Example 1. Example 10 HAP 5g, sodium chondroitin sulfate 5
g, sodium hyaluronate (molecular weight approximately 1 million)
0.5g, glucomannan, 5g, and epichlorohydrin 9.25g were mixed in 100ml of 0.01N NaOH aqueous solution, and reacted according to Example 1 to obtain 16.3g of cartilage-like substance.
I got it. Analysis value Ca 9.1% P 5.5% Glucuronic acid equivalent uronic acid value 7.2% Water 28.7% Test example 1 Resistance to enzymatic degradation As a model of deterioration reaction during biological implantation, resistance to hyaluronidase, a mucopolysaccharide degrading enzyme, was investigated. . 1 g of the cartilage-like material obtained in Example 1 was approximately 1 mm 3
Shred into square pieces and add in 0.1M acetate buffer (PH5.0) 50
ml, add 0.1 g of bovine testicle hyaluronidase (Seikagaku Corporation, reagent grade) and incubate at 50℃ for 24 hours.
Stir and digest for hours. The cartilage-like material piece was separated and the liquid was measured by the carbazole sulfuric acid method, but no uronic acid was found in the liquid. This revealed that this sample was not easily degraded by hyaluronidase and was not easily degraded in vivo. 2 Blood compatibility test As an indicator of biocompatibility, blood coagulation reaction, platelet aggregation reaction, The effect of this sample on hemagglutination reaction was qualitatively evaluated. The bottom of a polyethylene tube with a diameter of 0.7 cm and a length of 4 cm was clamped and filled with 30 square pieces of 1 mm 3 of cartilage-like material prepared in Example 1, and 1 to 2 ml of freshly collected human venous blood was added. Ta. The control clotting time was measured by adding the sample and blood to a glass tube of the same size as the tube. Blood fluidity was examined by heating each tube and glass tube to 37°C and tilting them every 30 seconds. The end point of the coagulation time was defined as the time when the entire blood turned into a gel. Control-1 was obtained by treating only blood in the same manner without adding the main sample. The results are shown in the table.

【表】 全く対照−1と同じ結果を示し血液適合性を
有することが判つた。 3 成猫腹部皮下埋植試験 実施例2、実施例10、比較例1の1.0cm×1.0
cm×1mmの板状検体片を生理食塩液により膨潤
させ各検体当り6匹の成猫(体重2.5〜3Kg)
の腹部皮下に埋植した。2週後及び4週後に各
3匹ずつ屠殺し埋植片及び周囲の組織の病理組
織所見を観察した。結果を表に示す。
[Table] The results were exactly the same as Control-1, and it was found to be blood compatible. 3 Adult cat abdominal subcutaneous implantation test Example 2, Example 10, Comparative Example 1 1.0 cm x 1.0
A plate-shaped sample piece of cm x 1 mm was swollen with physiological saline and 6 adult cats (weight 2.5-3 kg) were prepared for each sample.
It was implanted subcutaneously in the abdomen. Two and four weeks later, three animals each were sacrificed and histopathological findings of the implants and surrounding tissues were observed. The results are shown in the table.

【表】【table】

【表】 以上の病理組織所見より、本発明の骨類似成形
物は初期軽度の異物反応を経て、組織適合状態で
終結をみた。一方、GAGを含まない比較例1の
検体は、強い異物反応及び炎症反応ののち、完全
に劣化分解されることが判る。
[Table] From the above histopathological findings, the bone-like molded product of the present invention underwent an initial mild foreign body reaction and ended up in a tissue-compatible state. On the other hand, it can be seen that the sample of Comparative Example 1, which does not contain GAG, is completely degraded and decomposed after a strong foreign body reaction and inflammatory reaction.

Claims (1)

【特許請求の範囲】[Claims] 1 ハイドロキシアパタイト、グリコサミノグリ
カン、グリコマンナン及びエピハロヒドリンを反
応せしめてなることを特徴とする骨類似成形物。
1. A bone-like molded product characterized by reacting hydroxyapatite, glycosaminoglycan, glycomannan, and epihalohydrin.
JP61015862A 1986-01-29 1986-01-29 Bone analogous molded article Granted JPS62176454A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61015862A JPS62176454A (en) 1986-01-29 1986-01-29 Bone analogous molded article

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61015862A JPS62176454A (en) 1986-01-29 1986-01-29 Bone analogous molded article

Publications (2)

Publication Number Publication Date
JPS62176454A JPS62176454A (en) 1987-08-03
JPH0360272B2 true JPH0360272B2 (en) 1991-09-13

Family

ID=11900608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61015862A Granted JPS62176454A (en) 1986-01-29 1986-01-29 Bone analogous molded article

Country Status (1)

Country Link
JP (1) JPS62176454A (en)

Also Published As

Publication number Publication date
JPS62176454A (en) 1987-08-03

Similar Documents

Publication Publication Date Title
KR100730527B1 (en) Hyaluronic acid gel composition, preparation method thereof and medical material containing same
US5470911A (en) Glycosaminoglycan-synthetic polymer conjugates
Barbosa et al. Polysaccharides as scaffolds for bone regeneration
Pighinelli et al. Chitosan–hydroxyapatite composites
US9050392B2 (en) Hydrogel and biomedical applications thereof
RU2230752C2 (en) Cross-linked hyaluronic acids and their application in medicine
KR100395724B1 (en) Hard Tissue Stimulating Agent
CA2377544C (en) Hyaluronic acid anti-adhesion barrier
JPH0669490B2 (en) Implant for preventing adhesion between body tissues and method for producing the same
US20100178313A1 (en) Implantable Degradable Biopolymer Fiber Devices
JP2005535736A (en) Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
Kodavaty Poly (vinyl alcohol) and hyaluronic acid hydrogels as potential biomaterial systems-A comprehensive review
CN117298355B (en) Coated hyaluronic acid gel composition and preparation method and application thereof
US20090022770A1 (en) Chitosan Compositions
CN114099787A (en) Absorbable biological membrane, preparation method and application thereof
CN116942903B (en) A bone regeneration material and its preparation method
JPH0360272B2 (en)
CN119997988A (en) 3D printed bioactive scaffolds
JPH0826081B2 (en) Method for insolubilizing N-carboxyalkyl derivative of chitosan
EP3533806A1 (en) Gel composition and method for producing same
WO2006076659A2 (en) Composition and method for covalently coupling a substance to a substrate
Kocak INJECTABLE TISSUE ENGINEERING MATERIALS
CN119424746A (en) An injectable hydrogel for cartilage damage repair and preparation method thereof
Pighinelli et al. Chitosan-Calcium Phosphate Complex Composite

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees